Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9875

Clinical Safety of Chemotherapy for Elderly Cancer Patients Complicated with Hypertension  

Qian, Ya-Dong (Deaprtment of Internal Medicine, Gao Gang People Hospital)
Xu, Xu (Deaprtment of Internal Medicine, Gao Gang People Hospital)
Wang, Lin (Deaprtment of Internal Medicine, Gao Gang People Hospital)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9875-9877 More about this Journal
Abstract
Objective: To access the safety of chemotherapy for elderly cancer patients complicated with hypertension. Methods: Elderly cancer patients who were complicated with hypertension and treated by chemotherapy were recruited. All patients were treated by chemotherapy after an intervention on hypertension by psychotherapy, exercise guidance, salt regulation and nutrition support, therapy on hypertension, as well as prevention on hypertension associated complications. Results: In 68 eligible patients, two suspended chemotherapy because of adverse reactions and 4 because of disease progression. The remaining 62 patients completed chemotherapy smoothly based on good hypertension control. Conclusion: With effective control of blood pressure, chemotherapy for elderly cancer patients complicated with hypertension is generally safe.
Keywords
Elderly cancer patients; hypertension complications; chemotherapy; safety;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Cao Y, Tan A, Gao F, et al (2009). A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis, 24, 677-85.   DOI
2 Choi KH, Park SM, Lee K, et al (2013). Prevalence, awareness, control, and treatment of hypertension and diabetes in Korean cancer survivors: a cross-sectional analysis of the fourth and fifth Korea national health and nutrition examination surveys. Asian Pac J Cancer Prev, 14, 7685-92.   과학기술학회마을   DOI
3 Daher IN, Yeh ET (2008). Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med, 5, 797-805.   DOI
4 Havlik RJ, Yancik R, Long S, Ries L, Edwards B (1994). The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6.   DOI   ScienceOn
5 Izzedine H, Ederhy S, Goldwasser F, et al (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 20, 807-15.   DOI   ScienceOn
6 Jain M, Townsend RR (2007). Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep, 9, 320-8.   DOI   ScienceOn
7 Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JWW (1998). Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer, 21, 105-13.   DOI   ScienceOn
8 Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al (2004). Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax, 59, 602-7.   DOI
9 Ko C, Chaudhry S (2002). The need for a multidisciplinary approach to cancer care. J Surg Res, 105, 53-7.   DOI   ScienceOn
10 Lopez-Encuentra A (2002). Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer, 35, 263-9.   DOI
11 Pereira A, Garmendia ML, Alvarado ME, Albala C (2012). Hypertension and the risk of breast cancer in Chilean women: a case-control study. Asian Pac J Cancer Prev, 13, 5829-34.   과학기술학회마을   DOI
12 Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL., Jr (2004). Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA, 291 2441-7.   DOI
13 Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens, 23, 460-8.   DOI   ScienceOn
14 Satariano WA, Ragland DR (1994). The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med, 120, 104-10.   DOI   ScienceOn
15 Smith AW, Reeve BB, Bellizzi KM, et al (2008). Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev, 29, 41-56.
16 Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005). Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 294, 1765-72.   DOI   ScienceOn
17 Townsend RR (2006). Hypertension and cancer chemotherapies. In: Mohler ER, Townsend RR, editors. Advanced Therapy in Hypertension and Vascular Disease. Toronto, Canada: BC Decker; 2006. pp. 502-7.
18 Yeh ETH (2006). Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med, 57, 485-98.   DOI
19 Yancik R, Wesley MN, Ries LA, et al (1998). Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer, 82, 2123-34.   DOI   ScienceOn
20 Yancik R, Wesley MN, Ries LAG, et al (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 285, 885-92.   DOI   ScienceOn